| | |
ASPsiRNA information |
siRNA Id: | aspsirna1929
|
siRNA Name: | si747/49_3D9
|
Mismatch information |
Wild siRNA (As strand 3'->5'): | AUAGUUCCUUAAUUCUCUUCGUUGUAGA
|
ASP-siRNA (As strand 3'->5'): | AUAGUUCCUU----------GUUGUAGA
|
Mismatch position in siRNA: | DEL_10,11,12 |
Gene Information |
Gene Name | epidermal growth factor receptor (EGFR) |
Target Sequence (5'->3'): | UAUCAAGGAACCAACAUCU
|
Wild allele (5'->3'): | UAUCAAGGAAUUAAGAGAAGCAACAUCU
|
Mutant allele (5'->3'): | UAUCAAGGAA----------CAACAUCU
|
Position of siRNA on target gene: | 2475-2502
|
Respective Gene/Protein Resources |
GenBank Accession: | NM_005228.3 |
Cytogenic location: | 7p11.2 |
Chromosomal coordinates: | 7:55,086,677-55,279,261 |
UniProt ID: | P00533 |
HUGO ID: | 3236 |
Reference SNp(RefSNP): | rs12191322 |
Disease/Mutation information |
Target Mutation: | c.2248G>C,p.A750P
|
Matation type/variant: | single nucleotide variant/Missense variant
|
Mutation at gene level: | NG_007726.3:g.160754G>C
|
Pathogenic status of mutation: | Uncertain significance
|
Disease: | Cancer |
Clinical Resources |
ClinVar ID: | 45239 |
KEGG disease ID: | H00013 |
OMIM ID: | 211980 |
COSMIC: | EGFR |
DECIPHER: | EGFR |
GeneTests: | EGFR |
ASP siRNA details |
Mutant allele (5'->3'): | UAUCAAGGAA----------CAACAUCU
|
ASP-siRNA (As strand 3'->5'): | AUAGUUCCUU----------GUUGUAGA
|
Percentage efficacy of ASP-siRNA for mutant allele: | 82
|
Wild allele (5'->3'): | UAUCAAGGAAUUAAGAGAAGCAACAUCU
|
ASP-siRNA (As strand 3'->5'): | AUAGUUCCUU----------GUUGUAGA
|
Percentage efficacy of ASP-siRNA for wild allele: | 0
|
Relative difference: | 82
|
Wild siRNA details |
Wild allele (5'->3'): | UAUCAAGGAAUUAAGAGAAGCAACAUCU
|
Wild siRNA (As strand 3'->5'): | AUAGUUCCUUAAUUCUCUUCGUUGUAGA
|
Percentage efficacy of wild siRNA for wild allele: | 59
|
Wild allele (5'->3'): | UAUCAAGGAAUUAAGAGAAGCAACAUCU
|
ASP-siRNA (As strand 3'->5'): | AUAGUUCCUU----------GUUGUAGA
|
Percentage efficacy of Wild sirna for mutant allele: | 11
|
Relative difference : | 48
|
General information |
Mismatch incorporated in siRNA/Target: | siRNA |
Cell-line used: | HeLa |
Experimental technique used: | Dual luciferase reporter assay |
Transfection method: | Lipofectamine 2000 |
siRNA expression method: | Applied Biosystems |
Post-transfection duration: | 24 hours |
Concentration used: | 20nM |
Reference: | 23951344 |
Delivery method: | Atelocollagen mediated delivery |
'Article title: | Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference. |
'Authors: | Takahashi M, Chiyo T, Okada T, Hohjoh H. |
'Journal Reference: | PLoS One. 2013 Aug 8;8(8):e73214. doi: 10.1371/journal.pone.0073214. eCollection 2013. |
'